The Cellex, Inc. qSARS-CoV-2 IgG/IgM Rapid Test, which has received an Emergency Use Authorization (EUA) from the U.S Food and Drug Administration (FDA), is indicated for the qualitative detection and differentiation of IgM and IgG antibodies against SARS-CoV-2 in serum, plasma (EDTA or citrate), or venipuncture whole blood from individuals suspected of COVID-19 by a healthcare provider.
- Turnaround Time: 15-20 minutes
- Specimen Type: Serum, plasma (EDTA or citrate), or venipuncture whole blood
- 25 kits/carton
The Cellex, Inc. qSARS-CoV-2 IgG/IgM Rapid Test is manufactured and approved for use by the Therapeutic Goods Administration (TGA) .
Buy Cellex, Inc. qSARS-CoV-2 IgG/IgM Rapid Test for Your WorkPlace
If your company or organisation is interested in rapid testing solutions, contact us today for help procuring the Cellex, Inc. qSARS-CoV-2 IgG/IgM Rapid Test or other rapid tests authorised by the Therapeutic Goods Administration (TGA) .
If you’re interested in rapid testing solutions, contact us today for a quote. You can also place an order for the Cellex, Inc. qSARS-CoV-2 IgG/IgM Rapid Test or other rapid tests approved by the TGA.
Our team at Rapid Tests Australia can also assist with implementing a rapid testing program to protect your workplace from the risks of COVID-19.
